Skip to content
★ Sign in to follow
RP

Robert Peabody

CFO
Lineage Cell Therapeutics, Inc.Asterias Biotherapeutics, Inc.
Total declarations
6
Companies
2
▲ Purchases (1 ops.)
€17k
▼ Sales (1 ops.)
€197k

Latest filing published 19 Aug 2014 for Asterias Biotherapeutics, Inc..

Insider track record

Disclosed buys
1
Disclosed sells
1
Signal history

No signal scores available.

Closed purchases

Market purchases
1

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Since each purchase

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Robert Peabody: trading record in brief

Robert Peabody discloses dealings in 2 companies, chiefly Lineage Cell Therapeutics, Inc. and Asterias Biotherapeutics, Inc. Between 22 June 2011 and 15 August 2014, the trades on record add up to 6 filings.

Both buying and selling appear: 1 purchase worth €17k, against 1 sale worth €197k. Sales outweigh purchases by €180k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant and 2 option exercises. So far in 2014, the count stands at no purchases and 1 sale.

On 19 August 2014 came the latest disclosure, a transaction in Asterias Biotherapeutics, Inc. The clock since the last published purchase (23 June 2011) now reads 5,618 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Robert Peabody

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations6 total

6 of 6 declarations